Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985270 | 0.83 | AOC3 (0.55) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| SCHEMBL7214872 | 0.83 | AOC3 (0.51) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| SCHEMBL12862698 | 0.79 | MAPT (0.53) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| Ammonia Solution, Strong SCHEMBL28403781 | 0.78 | MAPT (0.51) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| SCHEMBL29248891 | 0.77 | AOC3 (0.49) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| SCHEMBL15064968 | 0.77 | AOC3 (0.59) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| SCHEMBL2880443 | 0.77 | MAPT (0.81) | L3MBTL1MAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL10101799 | 0.76 | MAPT (0.47) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| SCHEMBL30546852 | 0.76 | CYP11B1 (0.60) | L3MBTL1MAPTTDP1MAPK1AOC3 | |
| SCHEMBL29248898 | 0.76 | CYP11B1 (0.60) | L3MBTL1MAPTTDP1MAPK1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2807171-B1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2020-08-12 | — | — | EP | disclosed |
| US-9624234-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624234-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-06 | — | — | US | disclosed |
| US-6503898-B1 | Administering 4,7-dibenzyl-5,6-dihydroxy-N,N*-di(m-aminobenzyl)--1,3-diazepin-2-one or salt to treat human immunodeficiency virus infection | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | AGTR2, AGTR1, OPRL1 | L3MBTL1 4743/4885MAPT 3246/4885TDP1 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.